BB
BBNX.US Beta Bionics, Inc. Common Stock
- Market cap
- USD 893M
- P/E
- -
- P/B
- 2.23x
- ROE
- -23.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BBNX.US undervalued?
Graham numberThe Graham number of Beta Bionics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beta Bionics, Inc. Common Stock fundamental analysis
No fundamental analysis for Beta Bionics, Inc. Common Stock yet.
Beta Bionics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and ad…
Full company profileBeta Bionics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beta Bionics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 179K | 12.0M | 65.1M | 100M | 127M |
| Gross Profit | 179K | 6.31M | 35.9M | 55.5M | 74.2M |
| Operating Income | -65.8M | -35.9M | -45.3M | -71.7M | -102M |
| EBITDA | -62.7M | -42.0M | -52.5M | -70.3M | -94.2M |
| Net Income | -64.8M | -44.1M | -54.8M | -73.2M | -92.9M |
| EPS | -1.51 | -1.03 | -1.28 | -1.81 | -2.00 |
| Balance Sheet | |||||
| Total Assets | 35.5M | 110M | 150M | 329M | 444M |
| Total Liabilities | 206M | 51.4M | 73.6M | 41.1M | 42.4M |
| Shareholders' Equity | -170M | 58.6M | 76.0M | 288M | 401M |
| Cash & Short-term Investments | 27.7M | 96.7M | 104M | 219M | 240M |
| Total Debt | 4.13M | 4.22M | 7.26M | 7.30M | 6.10M |
| Cash Flow | |||||
| Operating Cash Flow | -60.2M | -32.4M | -48.3M | -50.9M | -67.7M |
| Capital Expenditure | 772K | 402K | 3.40M | 5.30M | 6.25M |
| Free Cash Flow | -61.0M | -32.8M | -51.7M | -56.2M | -73.9M |
| Ratios | |||||
| ROE | - | -75.2% | -72.0% | -25.5% | -23.1% |
| ROA | -182.3% | -40.1% | -36.6% | -22.3% | -20.9% |
| Net Profit Margin | -36,173.7% | -367.6% | -84.1% | -73.0% | -73.2% |
| Debt to Equity | - | 0.07x | 0.10x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beta Bionics, Inc. Common Stock dividends
Beta Bionics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Beta Bionics, Inc. Common Stock
- Insiders 0.86%
- Institutions 99.14%
- Public & others 0.00%
- Shares outstanding 54.4M
- Free float 42.7M
Top funds holding BBNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Gilead N | 3.98M | 7.33% | +6.21% | Jun 2026 |
| T. Rowe Price Health Sciences | 2.41M | 4.43% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 2.28M | 4.19% | +143.15% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 2.05M | 3.77% | 0.00% | Jun 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.68M | 3.08% | +31.71% | Sep 2026 |
| iShares Russell 2000 ETF | 1.03M | 1.89% | 0.00% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 770K | 1.42% | +51.61% | Sep 2026 |
| Bruce | 666K | 1.22% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 446K | 0.82% | +0.18% | Aug 2026 |
| JPMorgan Small Cap Growth A | 397K | 0.73% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 385K | 0.71% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 354K | 0.65% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Mid Cap ETF | 307K | 0.56% | -1.04% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 240K | 0.44% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 237K | 0.44% | +1.27% | Sep 2026 |
| iShares US Medical Devices ETF | 215K | 0.40% | -1.12% | Oct 2026 |
| T. Rowe Price Integrated US SMCC Eq I | 213K | 0.39% | +42.23% | Sep 2026 |
| JPMorgan Small Cap Value I | 212K | 0.39% | -2.06% | Sep 2026 |
| Fidelity Extended Market Index | 210K | 0.39% | +4.76% | Sep 2026 |
| Eventide Exponential Technologies I | 173K | 0.32% | 0.00% | Sep 2026 |
Top institutions holding BBNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 6.25M | 11.50% | +5.18% | Jun 2026 |
| Soleus Capital Management, L.P. | 4.39M | 8.08% | +0.90% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.27M | 7.85% | +0.93% | Jun 2026 |
| Sands Capital Ventures, LLC | 3.71M | 6.82% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.34M | 6.14% | +9.92% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.25M | 4.15% | -10.71% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.78M | 3.28% | +3.15% | Jun 2026 |
| Vestal Point Capital LP | 1.60M | 2.94% | -27.65% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.50M | 2.76% | -25.00% | Jun 2026 |
| Deerfield Management Co | 1.32M | 2.44% | 0.00% | Jun 2026 |
| Omega Fund Management LLC | 1.32M | 2.42% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 1.25M | 2.30% | -11.69% | Jun 2026 |
| Divisadero Street Capital Management, LP | 1.11M | 2.05% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.07M | 1.97% | +15.09% | Jun 2026 |
| State Street Corp | 970K | 1.78% | +2.55% | Jun 2026 |
| Millennium Management LLC | 956K | 1.76% | +11.08% | Jun 2026 |
| Balyasny Asset Management LLC | 856K | 1.57% | +38.48% | Jun 2026 |
| Perceptive Advisors LLC | 833K | 1.53% | -1.19% | Jun 2026 |
| JPMorgan Chase & Co | 703K | 1.29% | +128.94% | Jun 2026 |
| Bruce & Co Inc | 666K | 1.22% | +20.88% | Jun 2026 |
Beta Bionics, Inc. Common Stock company profile
- Company name
- Beta Bionics, Inc. Common Stock
- Ticker
- BBNX.US
- Exchange
- USA Stocks
- Listed since
- Jan 30, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 420
- Fiscal year end
- December
- Address
- 11 Hughes, Irvine, CA, United States, 92618
- Phone
- 949 427 7785
- Website
- betabionics.com
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Beta Bionics, Inc. Common Stock management
8- Mr. Sean T. Saint PEPresident, CEO & Director · born 1976
- Mr. Stephen H. FeiderCFO, Treasurer & Secretary · born 1990
- Mr. Mike MensingerChief Product Officer · born 1978
- Mr. David HendersonVice President of Operations
- Blake BeberHead of Investor Relations
- Ms. Felicia SanbornVice President of Marketing
- Dr. Steven Russell M.D., Ph.D.Chief Medical Officer · born 1969
- Mr. Mark Hopman M.B.A., R.Ph.Chief Commercial Officer · born 1978